Regeneron’s COVID-19 Outpatient Trial Demonstrates that REGN-COV2 Significantly Reduced Viral Load and Need for Further Medical Attention

Results shared with the U.S. FDA, which is reviewing an Emergency Use Authorization submission for the REGN-COV2 low dose in adults with mild-to-moderate COVID-19 who are at high risk for poor outcomes. Regeneron asserts that data provides definitive final virology results and meets the clinical endpoint of reducing medical visits Ocober 28, 2020. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) […]

Eli Lilly Antibody Treatment Not Effective for Hospitalized Patients with Severe COVID-19 – Early Use is Key

Early Use of Monoclonal Antibodies Deemed Important for Effectiveness In an update on October 26, Eli Lilly stated that the pause of the ACTIV-3 trial was made permanent. The reason was not a safety issue with the antibody treatment – i.e. unanticipated side effect – but rather that it was ineffective on patients already hospitalized […]

Vir Biotechnology and GlaxoSmithKline Start Phase 3 Trials of Their Antibody Drug

Vir Biotechnology and GlaxoSmithKline on Tuesday said they will begin the Phase 3 portion of clinical testing for their experimental coronavirus antibody drug, VIR-7831, following positive safety data from the initial part of the study. Vir and GSK skipped over the usual small Phase 1 safety studies and pushed straight into a mid-stage trial with a plan to expand […]

AstraZeneca’s COVID-19 Long-Acting AntiBody (LAAB) Combination Receives $486M to Accelerate Trials and Production

AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been engineered with AstraZeneca’s proprietary half-life extension technology to increase the durability of the therapy for six […]

Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial

Critics said the study, sponsored by the W.H.O., was too poorly conducted to be definitive. Remdesivir, the only antiviral drug authorized for treatment of Covid-19 in the United States, fails to prevent deaths among patients, according to a study of more than 11,000 people in 30 countries sponsored by the World Health Organization. The drug was granted emergency authorization by the Food […]

Scroll to top